SecBot SecBot

Prescription Drug Supply Chain Pricing Transparency Act

H.R. 7535 Rep. Yadira Caraveo (D-CO-8) In committee
Bill text PDF
  1. Introduced Mar 5
  2. Committee Mar 5
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Mar 5, 2024Next: House vote
680d ago Dec 17, 2024: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Subscribe to see spend
Member trades
3trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Financials 1
Search all 1 companies, their asks and price moves Subscribe

Summary

This bill requires the Government Accountability Office (GAO) to study and report on compensation and payment structures in the prescription drug supply chain that are based on a drug's price. Sec. 2, GAO study and report: The Comptroller General must conduct a study covering the types, magnitude, and prevalence of price-related compensation (like fees as a percentage of drug price) among intermediaries such as pharmacy benefit managers, plan sponsors, wholesalers, pharmacies, manufacturers, and others. The study must also examine business models, variation between affiliated and unaffiliated entities, potential conflicts of interest, patterns over time, factors driving use of such structures, and other relevant issues. A report with findings and recommendations must be submitted to Congress within two years of enactment.

Summary of the bill text as introduced in House (Mar 5, 2024), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.